NCCN Guidelines Include an Abundance of Options Across Multiple Myeloma Paradigm The National Comprehensive Cancer Network (NCCN) guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients, said Shaji K. Kumar, MD, during the 2021 […]

Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 – 2027: By … global Multiple Myeloma Treatment market 2019. The report will give the past market trends from 2017 and forecast from 2021 to 2026 by considering 2020 a differently. The report forecast that market for Multiple Myeloma Treatment will reach to XX Bn by […]

Goldman Sachs Bets on These 3 Stocks; Sees Over 50% Upside Potential What goes up must come down, as we all know. This fact of physics is the underlying worry of the stock market, that fuels our suspicions of bubbles. But investment firm Goldman Sachs doesn’t believe we should worry; the firm’s chief global equity […]

Global Melphalan Market 2021– Industry Insights, Drivers, Top Trends, Global Analysis And … “A SWOT Analysis of Melphalan, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down.” The global “Melphalan market” research report offers a comprehensive analysis and forecasts of the Melphalan market at both the global and […]

Latest updates on treating plasma cell dyscrasias Meral Beksac, MD, Ankara University, Ankara, Turkey, shares the latest updates on the treatment of plasma cell dyscrasias, as presented at EBMT 2021. Dr Beksac outlines the discovery and utilization of novel biomarkers, such as translocation of (11;14), as well as new data from the Phase III ANDROMEDA […]

FDA Approves Ide-Cel for Relapsed/Refractory Multiple Myeloma The FDA has approved idecabtagene vicleucel (ide-cel; formerly bb2121; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody.1 Ide-cel represents the first B-cell maturation antigen […]

A Phase III Study Comparing JNJ-68284528 CAR T-Cell Therapy with a Combination of Standard … Full Title A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, vs Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma […]

Bariatric surgery significantly reduces cancer risk for certain patients, finds study New Jersey [US], March 26 (ANI): Bariatric surgery can significantly reduce the risk of cancer–and especially obesity-related cancers–by as much as half in certain individuals, according to a study.The study led by researchers at Rutgers Robert Wood Johnson Medical School’s Center for Liver Diseases […]

Chemotherapy Types and the Cancers They’re Used For Cancer is a large group of conditions caused by the rapid division of abnormal cells. Chemotherapy is one treatment option that involves receiving medication that keeps cancer cells from spreading. Chemotherapy can be effective either on its own or with other treatments. But it also has the […]

Many Options, Many Updates to NCCN Guidelines in Multiple Myeloma Although the combination of bortezomib, lenalidomide, and dexamethasone remains the foundation the standard initial therapy for patients newly diagnosed with multiple myeloma (MM), the options for what to do next—including the timing of a stem cell transplant—have proliferated, and that is reflected in updates to […]